Meeting
2022 ASCO Annual Meeting
Comparative efficacy of novel combination immunotherapy strategies for unresectable hepatocellular carcinoma (HCC): A network metanalysis of landmark phase III trials.
Authors
Claudia A.M. Fulgenzi
Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom
Claudia A.M. Fulgenzi , Antonio D'Alessio , Lorenza Scotti , Chiara Airoldi , Demirtas Coskun , Alessandra Gennari , Alessio Cortellini , David J. James Pinato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4098)
DOI
10.1200/JCO.2022.40.16_suppl.4098
Abstract #
4098
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.
First Author: Claudia A.M. Fulgenzi
Poster
2021 ASCO Annual Meeting
The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
First Author: David Trueman
Poster
2020 ASCO Virtual Scientific Program
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
First Author: Arndt Vogel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
First Author: Chloe Lim